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The effect of an exon 12 polymorphism of the human thromboxane synthase 
(CYP5A1) gene in stroke patients 
Abstract 
Background: To examine the prevalence of an exon 12 polymorphism on the human Thromboxane 
synthase (CYP5A1) gene. 
Material/Methods: Using sequence-specific PCR, we examined the allelic prevalence in 237 Greek 
patients with ischemic strokes and in 171 controls. In addition, we compared the CYP5A1 allelic 
prevalence in 71 patients with stroke recurrence despite Aspirin use, in comparison with patients who 
have not experienced recurrent stroke while taking Aspirin. 
Results: The frequencies of the CYP5A1*9mutant (substitution of guanine by adenine near the heme-
binding catalytic domain) and of the wild-type allele were 0.197 and 0.803, respectively; they did not differ 
significantly between stroke patients and controls. The wildtype allele was more frequent in the Cretan 
population compared to continental Greece (OR 1.80, 95% CI 1.19-2.74). The wild-type allele was more 
frequent among hypertensive and less frequent among diabetic stroke sufferers, respectively. The 
CYP5A1*9 mutant was significantly more prevalent among stroke patients with history of previous 
cerebrovascular attacks (p 
Conclusions: Allelic prevalence of the CYP5A1 exon 12 might differ between geographic areas within the 
same ethnic group, and is associated with particular characteristics of stroke patients. Allele mutations 
can abolish the enzymatic activity of thromboxane synthase, via impaired heme binding, associated with 
defective response to Aspirin used as secondary prevention, an effect independent from the conventional 
risk factors for cerebrovascular disease. 
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Summary
 Background: To examine the prevalence of an exon 12 polymorphism on the human Thromboxane synthase 
(CYP5A1) gene.
 Material/Methods: Using sequence-specifi c PCR, we examined the allelic prevalence in 237 Greek patients with isch-
emic strokes and in 171 controls. In addition, we compared the CYP5A1 allelic prevalence in 71 
patients with stroke recurrence despite Aspirin use, in comparison with patients who have not ex-
perienced recurrent stroke while taking Aspirin.
 Results: The frequencies of the CYP5A1*9 mutant (substitution of guanine by adenine near the heme-bind-
ing catalytic domain) and of the wild-type allele were 0.197 and 0.803, respectively; they did not dif-
fer signifi cantly between stroke patients and controls. The wild-type allele was more frequent in the 
Cretan population compared to continental Greece (OR 1.80, 95% CI 1.19–2.74). The wild-type al-
lele was more frequent among hypertensive and less frequent among diabetic stroke sufferers, re-
spectively. The CYP5A1*9 mutant was signifi cantly more prevalent among stroke patients with his-
tory of previous cerebrovascular attacks (p<0.01); and among those who failed secondary Aspirin 
prophylaxis even after adjusting for the common risk factors for cardiovascular disease (OR 1.49, 
95% CI 1.06–2.11).
 Conclusions: Allelic prevalence of the CYP5A1 exon 12 might differ between geographic areas within the same 
ethnic group, and is associated with particular characteristics of stroke patients. Allele mutations 
can abolish the enzymatic activity of thromboxane synthase, via impaired heme binding, associat-
ed with defective response to Aspirin used as secondary prevention, an effect independent from 
the conventional risk factors for cerebrovascular disease.
 key words: aspirin • CYP5A1 • arachidonic acid • single-nucleotide polymorphism • stroke • 
thromboxane synthase • transient ischemic attack
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BACKGROUND
Cerebrovascular attacks are leading cause of mortality and 
morbidity worldwide [1]. In more than 80% of cases, they 
consist of ischemic events within the lumen of cerebral ves-
sels [2], a process in which primary hemostasis and plate-
lets play a cardinal role [3]. Antiplatelet agents, primarily 
Aspirin, remain the optimal treatment for primary and sec-
ondary prevention of ischemic strokes [4]. The benefi cial 
action of Aspirin on strokes is affected via inhibition (irre-
versible acetylation) of the enzyme cyclo-oxygenase, result-
ing in reduced thromboxane A2 formation. Thromboxane 
A2 favors platelet aggregation and vasoconstriction [5]. The 
synthetic pathway that leads to thromboxane A2 formation 
results in the metabolism of arachidonic acid to prostaglan-
din and leucotriene derivatives via the sequential activation 
of several enzymes [6].
One of the key enzymes in this process is the thromboxane 
synthase (CYP5A1). This is a unique member of family 5 
in the cytochrome P450 superfamily and catalyzes the con-
version of prostaglandin H2 to thromboxane A2 [7]. A bal-
ance between thromboxane A2 and prostacyclin production 
is very important for vessel integrity [6]. The mechanism, 
however, controlling the formation of these biofactors -
formed by isomerization of their common precursor pros-
taglandin H2-remains unknown. Clinically, a defi ciency of 
platelet CYP5A1 activity has been associated with moderate 
to severe bleeding disorders [8], but the molecular mecha-
nisms underlying this remain unclear.
The CYP5A1 gene encoding for thromboxane synthase 
has been characterised at the long arm of chromosome 7 
[9]. It consists of 13 exons and 12 introns, and its size ap-
proximates 150Kb. Alternate splicing of the CYP5A1 tran-
script has been described. The truncated CYP5A1 mRNA 
lacks the entire exon 12 encoding the heme-binding do-
main of the enzyme; the truncated protein is lacking enzy-
matic activity [10]. In the only relevant study published so 
far, genetic polymorphisms of the CYP5A1 gene have been 
described in a highly homogeneous French population of 
200 healthy volunteers of Caucasian origin: almost 10% of 
subjects exhibited at least one out of the 8 missense point 
mutations detected [11]. Among the latter, the substitution 
of guanine by adenine at the position 1397 of exon 12 sig-
nifi es the mutant allele designated as CYP5A1*9; the mu-
tation results in Glutamine replacing Arginine as the ami-
no acid 466 of thromboxane synthase [11]. This position is 
related to the heme-binding domain that is important for 
the catalytic activity of the encoded enzyme [12]. A muta-
tion has also been described in another (1425) position of 
exon 12, where substitution of cytosine by thymine leads to 
the silent (not causing any change in the encoded protein) 
polymorphic allele CYP5A1*1C [11].
Genetic studies have previously suggested the role of CYP 
genes in defi ning genetically susceptible individuals at risk 
for tobacco-related cancers, due to impaired hepatic detox-
ifi cation of tobacco substances [13]. In the present case-
control study we examined the prevalence of the known 
CYP5A1 exon 12 genetic polymorphism in stroke patients 
with and without Aspirin prophylaxis, as well as in healthy 
controls from the island of Crete in comparison with coun-
terparts from continental Greece.
MATERIAL AND METHODS
Recruitment of the study population was performed in 
two hospitals from different geographic areas of Greece: 
“Sotiria” University General Hospital in Athens; and the 
“Venizelion” General Hospital, Heraklion, Crete. Two hun-
dred and thirty seven consecutively admitted patients with 
a history of documented cerebral ischemic attack, as well 
as 171 subjects without a history of cerebrovascular attack 
were included in the study. Controls from each centre were 
matched to local stroke patients, in terms of age, sex, and 
major modifi able risk factors for cerebrovascular disease 
(smoking, hypertension, diabetes, dyslipidemia). To exam-
ine the association between the CYP5A1 SNPs and the pro-
tective effect of Aspirin, 71 patients with recurrent stroke 
while taking Aspirin were compared with the stroke patients 
who did not have any recurrent event while on aspirin sec-
ondary prophylaxis.
Recruitment study period was 1 year (September 2003–
August 2004). Non-contrast computerized tomography 
was performed on all patients within 24 hours of admis-
sion, repeated in the following 72 hours or supplemented 
by MRI, as appropriate. Additional examinations (i.e. lum-
bar puncture, septic work-up, etc) were performed as nec-
essary. Patients were excluded from the study if an alterna-
tive diagnosis (i.e. hematoma, encephalitis, tumour) was 
responsible for the neurologic fi ndings; if there was radio-
logic evidence of intracerebral hemorrhage or hemorrhag-
ic transformation; if they had a history of cancer or had re-
ceived chemotherapy and/or radiotherapy.
Since we focused on the role of CYP5A1 on the Aspirin path-
way, patients were also excluded if they had atrial fi brillation 
(where the mechanism of stroke is different, and the treat-
ment of choice does not entail Aspirin) or when the stroke 
was classifi ed of cardioembolic origin, as well as if they were 
on oral anticoagulants or antiplatelet therapy other than 
Aspirin (i.e. dipyridamole, clopidogrel). Stroke patients 
were classifi ed according to the TOAST diagnostic system 
[14]. Risk factors for cerebrovascular disease were assessed 
according to standard defi nitions [15]. Dyslipidemia was de-
fi ned by pharmacological treatment, total serum cholester-
ol >6.2 mmol/L or LDL-cholesterol >4.1 mmol/L.
During the 12 months of the recruitment period, 511 pa-
tients were considered for inclusion in the study. Out of 
those, intracerebral hemorrhage was diagnosed in 58; for 
another 70 patients an alternative intracerebral patholo-
gy (i.e. hematoma, tumour, infection) accounted for the 
neurologic fi ndings. A further 146 patients were exclud-
ed because of other reasons (cardioembolic stroke, atrial 
fi brillation and/or anticoagulation, use of other antiplate-
let treatment, refusal to provide sample, etc). Main charac-
teristics of patients and controls included in the study are 
shown in Table 1.
Peripheral blood from study subjects was collected in EDTA 
anticoagulated tubes. Genomic DNA was extracted from 
whole blood using proteinase K, followed by phenol ex-
traction and ethanol precipitation according to standard 
procedures [16]. DNA was resuspended in 50 μl TE buffer 
(10 mM Tris-HCl, 1 mM EDTA, pH 8.0). DNA purity was 
assessed by a UV/VIS spectrophotometer evaluating the 
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A260/A280 ratio. Working stocks were prepared by 10-fold di-
lution in double distilled H2O.
An allele-specifi c polymerase chain reaction (AS-PCR) ap-
proach [17] was used to detect the presence of polymor-
phisms at the 1397 site of exon 12. We designed sequence 
specifi c primers with mismatches at the 3’ end to identify 
each variant, which, in combination with a consensus prim-
er, resulted in a PCR product of expected size if the specifi c 
allelic variant was present. A set of appropriate control prim-
ers confi rmed PCR amplifi cation in the reactions where spe-
cifi c allele amplifi cation was absent: the presence of an al-
lele-specifi c band of the expected size in conjunction with 
a control band was considered to be positive evidence for 
each particular allele. The absence of an allele-specifi c band 
with presence of a control band was considered to be nega-
tive indication for a particular allele. The allele-specifi c and 
control primers we used are shown in Table 2.
PCR assays were performed by introducing 100 ng of ge-
nomic DNA in a PCR reaction mixture containing 1X PCR 
buffer, 250 μM dNTPs, 2.0 mM MgCl2, 0.2 mM each allele-
specifi c primer, 0.1 mM each control primer, and 0.2 U Taq 
DNA polymerase (Life Technologies Ltd., UK) to a 25 μl 
total reaction volume. The cycling parameters were as fol-
lows: 2 minutes at 95°C, 34 cycles of 30 seconds at 94°C, 50 
seconds at 60°C, and 25 seconds at 72°C, 21 cycles of 25 sec-
onds at 96°C, 50 seconds at 65°C, and 5 minutes at 72°C. 
The PCR products were visualized by agarose gel (2%) elec-
trophoresis after ethidium bromide staining.
To confi rm results produced by AS-PCR, randomly select-
ed samples (1 out of 10) from all variants (homozygous for 
each genotype and heterozygous) were analyzed by dye prim-
er cycle sequencing on an ABI 377 automated sequencer 
(PE Applied Biosystems, Warrington, UK), using the same 
allele-specifi c and consensus primer.
Data were analyzed using SPSS for Windows, release 12.0.1 
(SPSS, Chicago, IL, USA). To determine whether the distri-
bution of the exon 12 CYP5A1 genotypes fulfi lled the Hardy-
Weinberg equilibrium, the c2 test was used to compare the 
observed number of subjects with the expected number. In 
addition, continuous variables (i.e. age) were examined using 
one-way analysis of variance. Variables distributed in a non-
parametric fashion were examined using the Mann-Whitney 
U or the Kruskal-Wallis test, as appropriate. Normality was 
tested using the Kolmogorov-Smirnov test.
Our sample could provide us 90% power (with a 0.05) to de-
tect at least 10% difference in the prevalence of the rare al-
lele between stroke patients and controls, supposing the latter 
15%. For the same power and statistical signifi cance level, a 
sample of 133 patients would suffi ce for the detection of stroke 
recurrence on aspirin, should the mutant allele be overrep-
resented at an excess rate of 20% among stroke re-sufferers, 
in comparison to our reference stroke population.
In the stroke cohort, a logistic regression model was con-
structed to examine the relationship between CYP5A1 allelo-
types and stroke recurrence on Aspirin prophylaxis, using 
the following covariates: age, gender, stroke type, smoking 
status, diabetes mellitus, hypertension, dyslipidemia, use of 
statin and aspirin dose.
Patients N=237Controls N=171 p
Mean age (Range) 77.3 (47–99) 76.8 (43–96) NS
Sex
 Male (%) 114 (48.2) 83 (48.5) NS
 Female (%) 123 (51.8) 88 (51.5)
Origin
 Continental Greece (%) 173 (73) 125 (73.1) NS
 Crete (%) 64 (27) 46 (26.9)
Risk factors1
 None (%) 12 (5.1) 10 (5.8) NS
 One (%) 50 (21.1) 39 (22.8)
 More than one (%) 175 (73.8) 122 (71.4)
 Smokers (%) 73 (30.8) 53 (30.9) NS
 Hypertension (%) 193 (81.4) 133 (77.8) NS
 Diabetes (%) 92 (38.8) 56 (32.7) NS
 Dyslipidemia2 (%) 83 (35) 62 (36.2) NS
  Total chol. mmol/L
(mean ±SD)
6.6 (3.8) 6.4 (3.9)
  LDL-chol. mmol/L (mean 
±SD)
4.4 (3) 4.1 (3.1)
  HDL-chol. mmol/L (mean 
±SD)
1.1 (0.6) 1 (0.5)
Previous CVA3
 No evidence (%) 108 (45.6) NA
 One (%) 77 (32.5) NA
 More than one (%) 52 (21.9) NA
Classifi cation4
 TIA 28 (11.8) NA
 LVD 94 (39.7) NA
 SVD 82 (34.6) NA
 IU 33 (13.9) NA
Daily Aspirin dose NA
 No 166 (70)
 100 mg/day 15 (6.3) NA
 160 mg/day 27 (11.4) NA
 325 mg/day 29 (12.3) NA
Table 1. Main characteristics of the study population.
1  Denotes the major modifi able risk factors for cerebrovascular disease: 
smoking, hypertension, diabetes mellitus, dyslipidemia.
2  Presence of one of the following: pharmacological treatment, total 
serum cholesterol >6.2 mmol/L, LDL-cholesterol >4.1 mmol/L.
3  Includes ischemic strokes and/or documented transient ischemic 
attacks (TIA). CVA – cerebrovascular attack; NA – not applicable; NS 
– not statistically signifi cant.
4  According to the TOAST diagnostic system (see Ref. 14 for details): 
LVD – large-vessel disease; SVD – small-vessel disease; IU – ischemic 
stroke of undetermined etiology. Patients with cardioembolic 
disease, hemorrhage or acute stroke of etiology other (than ischemic) 
have been excluded from this study.
Basic Research Med Sci Monit, 2009; 15(1): BR30-35
BR32
Approval to conduct this research was obtained from Ethics’ 
Committees in both participating hospitals.
RESULTS
Representative examples of homozygous for the wild-type, 
CYP5A1*9 homozygous and heterozygous cases are shown 
in Figure 1. The allelic frequencies of the wild-type CYP5A1 
exon 12 and of the CYP5A1*9 mutant among the study popu-
lation were 0.803 and 0.197, respectively; these did not differ 
signifi cantly between stroke patients and controls (Table 3). 
There was under-representation of the CYP5A1*9 allele 
among Cretan subjects, compared with those originated from 
continental Greece (Odds Ratio for the wild-type 1.80, 95% 
Confi dence Intervals 1.19–2.74; p=0.005). This difference was 
observed even when stroke patients were analyzed separately 
(OR 1.81, 95% CI 1.04–3.14; p=0.036) (Table 3). Given this 
difference in allelic prevalence between mainland Greek and 
Cretan populations, the Odds Ratios for all following analysis 
in stroke patients were corrected for place of origin.
Among stroke patients, the presence of the CYP5A1 wild-
type allele was more frequent among the hypertensives (OR 
1.68, 95% CI 1.01–2.79; p=0.045), and less frequent among 
the diabetics (OR 0.55, 95% CI 0.36–0.84; p=0.006) (Table 
3). Also among stroke patients, the CYP5A1*9 mutant was 
signifi cantly more prevalent among those who suffered a re-
current stroke while receiving Aspirin, compared to those 
with successful secondary Aspirin prophylaxis (OR 1.73, 
95% CI 1.10–2.73; p=0.017). After adjusting for aspirin dose, 
use of statins and conventional risk factors for cardiovascu-
lar disease (age, gender, smoking status, diabetes mellitus, 
hypertension, dyslipidemia) the overrepresentation of the 
CYP5A1*9 mutant among stroke resufferers remained sta-
tistically signifi cant (OR 1.49, 95% CI 1.06–2.11; p=0.038) 
(Table 3). The adjusted allelic frequencies of the CYP5A1*9 
mutant among fi rst-ever stroke sufferers, patients with one 
previous stroke, and those with history of multiple cerebro-
vascular attacks were 0.199, 0.272, and 0.280, respectively; 
p<0.01 (Table 3). Regarding stroke types, the CYP5A1*9 mu-
tant was more prevalent among patients with small-vessel dis-
ease and (less so) among those with TIA compared with pa-
tients with large-vessel disease, but this difference was not 
statistically signifi cant in multivariate analysis (Table 3).
There was no association between the genotype distribution 
of exon 12 alleles and age, sex and the presence of risk fac-
tors for cardiovascular disease other than those in Table 3 
(i.e. family history, obesity, value of high-sensitivity C-reac-
tive protein, etc) (data not shown).
DISCUSSION
In this case-control study, we examined the allelic frequencies 
of a SNP on exon 12 of the thromboxane synthase (CYP5A1) 
gene in Greek stroke patients and controls. The allelic fre-
quency of the mutant CYP5A1*9 (that contains adenine in-
stead of guanine at the position 1397) was 0.197 among 
our study population; this was higher than the frequency of 
CYP5A1*9 (3.75%) found among another Caucasian (French) 
population in the only relevant study existing thus far [11]. 
Interestingly, the frequency of CYP5A1*9 was signifi cantly 
lower among the study subjects originating form the island 
Gene Polymorphism Annealing position Primer sequence Product size
CYP5A1 ex.12 +1397 G/A* 1375-1397 F- gctgaggcccggcagcagcaccg/A 120 bp
1495-1471 R- gcagcacgtggagcagtgtcaactt
GAPDH F- GGAAGGTGAAGGTCGGAGTCA 101 bp
R- GTCATTGATGGCAACAATATCCACT
Table 2. Primers for polymerase chain reaction amplifi cation of CYP5A1 exon 12 polymorphic sites.
* Position referred to the ATG translation start site as +1.
Figure 1.  Genotype analysis of CYP5A1 exon 12. Electrophoresis 
patterns for wild-type allele (top) and mutant 
allele (bottom). From left to right: Lanes 1, 2 and 4 
– heterozygous cases; Lane 5 – CYP5A1 wild-type 
homozygosity; Lane 6 – CYP5A1*9 homozygosity; Lane 
7 – 100bp DNA ladder.
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of Crete, compared with the continental Greek population; 
this difference was also observed when stroke patients were 
analysed separately. Different mutation frequencies among 
ethnic groups and subpopulations have been described for 
other polymorphic cytochromes P450 [18,19].
Prevalence of CYP5A1 allelic forms in our study did not 
signifi cantly differ between patients and controls. We 
note, however, that stroke sufferers despite Aspirin pro-
phylaxis were more likely to be carriers of the CYP5A1*9 
mutant than homozygous for the wild-type allele, even 
after adjusting for the common risk factors for cardio-
vascular disease. Similarly, the CYP5A1*9 mutant pre-
vailed among stroke patients with history of a previous 






CYP5A1 wt1 CYP5A1*92 OR (95% CI) CYP5A1 wt CYP5A1*9 OR (95% CI)
All 408 0.803 0.197
Status
 Patients 237 0.812 0.188 NS
 Controls 171 0.792 0.208
Origin
 Crete 110 0.855 0.145 1.80 (1.19–2.74) 64 0.859 0.141 1.81 (1.04–3.14)
  Continental 
Greece
298 0.765 0.235 173 0.772 0.228 
Smoking
 Yes 126 0.762 0.238 NS 73 0.822 0.178 NS
 No 282 0.761 0.239 164 0.750 0.250
Hypertension
 Yes 326 0.773 0.227 NS 193 0.782 0.218 1.68 (1.01–2.79)
 No 82 0.707 0.293 44 0.682 0.318 
Diabetes
 Yes 148 0.740 0.260 NS 92 0.701 0.299 0.55 (0.36–0.84)
 No 260 0.769 0.231 145 0.810 0.190 
Dyslipidemia
 Yes 145 0.755 0.245 NS 83 0.732 0.268 NS
 No 263 0.764 0.236 154 0.789 0.211 
Aspirin use3
 Yes 71 0.711 0.289 1.49 (1.06–2.11)6
 No 166 0.810 0.190
Previous CVA3,4 p<0.016
 No evidence 108 0.801 0.199
 One 77 0.728 0.272
 Multiple 52 0.720 0.280
Classifi cation5 NS6
 TIA 28 0.714 0.286
 LVD 94 0.782 0.218
 SVD 82 0.690 0.310
 IU 33 0.818 0.182
Table 3. Allelic frequencies of the CYP5A1 exon 12 among the study population.
1 Wild-type; 2 Allele that contains adenine instead of guanine at position +1397; 3 Among stroke patients only; 4 CVA – cerebrovascular attack; those 
include ischemic strokes and/or documented transient ischemic attacks (TIA); 5 LVD – large-vessel disease; SVD – small-vessel disease; IU – ischemic 
stroke of undetermined etiology; 6 Adjusted for age, sex, diabetes, hypertension, smoking, dyslipidemia, aspirin dose and statin use.
NS – not statistically signifi cant, OR – Odds Ratio (analysis for stroke patients was corrected for place of origin).
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Interestingly, correlations between the CYP5A1*9 allele and 
both hypertension and diabetes (two of the major risk factors 
for stroke) were also recorded in our population. The signif-
icance of these relationships remains to be clarifi ed; the fact, 
however, that overrepresentation of the mutant allele in pa-
tients resuffering from stoke while taking Aspirin remained 
after adjusting for the major risk factors for cardiovascular 
disease might imply for an independent role for this allele 
on the effi cacy of the arachidonic acid metabolism pathway. 
Interestingly also, all correlations in stroke patients remained 
signifi cant even after correction for place of origin, and this 
may signify for an effect of CYP5A1 on stroke pathophysiolo-
gy, additional to that conferred by ethnic predisposition.
Distribution of the mutated alleles did not differ among 
the different ischemic stroke subtypes in our study. This 
is particularly interesting for the case of the lacunar in-
farcts, whose pathophysiology is thought to differ from the 
rest ischemic strokes, and perhaps underlines the cardinal 
role of platelet-mediated thrombosis in the pathogenesis 
of brain infarcts [20].
A limitation to the interpretation of these results is that the 
metabolic activity of the genetic variants of thromboxane 
synthase has not been studied in depth as yet. Interestingly 
however, the CYP5A1*9 allele denotes a substitution near 
the heme-binding area of the protein [11]. Mutations in 
this area can abolish the enzymatic activity of thromboxane 
synthase, via impaired heme binding [12]. The increased 
frequency of the mutant CYP5A1*9 allele, interpreted in 
this context, may signify a population at risk for repeated 
ischemic strokes despite Aspirin prophylaxis, due to defec-
tive function of thromboxane synthase. The fi ndings at the 
gene level presented herein may herald the functional stud-
ies required to dismiss or validate the hypothesis above. In 
this context, the frequency and signifi cance of the alterna-
tive splicing that results in lack of the entire exon 12 need 
further investigation [21]. The effect of polymorphisms in 
other areas of the gene similarly merits further investiga-
tion. Finally, the validity of our results in other populations 
and ethnic groups remain to be determined.
The evaluation of the relationship between CYP5A1 polymor-
phisms and stroke recurrence is certainly restricted by the 
cross-sectional nature of our data. Unfortunately, the dura-
tion of Aspirin use could not be accurately assessed for large 
proportion of the stroke cohort, and this precluded from 
utilizing a time-dependent statistical approach. We note, 
however, signifi cant overrepresentation of the CYP5A1*9 
allele among patients with one, and multiple recurrenc-
es compared with those on “successful” Aspirin secondary 
prophylaxis. Another limitation to the interpretation of the 
results of this study is the absence of a validated surrogate 
marker for assessing compliance to aspirin. In addition, the 
degree of underlying cerebrovascular endothelial damage, 
potentially contributing to progression of the disease per se, 
could not be determined.
CONCLUSIONS
This study provides evidence for high prevalence of the 
CYP5A1*9 mutant among the Greek population. Our fi nd-
ings also imply that the presence of a mutant, affecting the 
heme-binding site of the enzyme, is possibly associated with 
recurrent cerebrovascular attacks in patients who fail second-
ary prophylaxis with Aspirin. Additional genetic and func-
tional studies of the other polymorphic variants described 
on the CYP5A1 gene are expected to clarify the role of the 
thromboxane synthase enzyme in cerebrovascular disease.
REFERENCES:
 1. Kistler JP: Atherothrombotic cerebrovascular disease – large and small 
vessels. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coro-
nary artery disease. Philadelphia: Lippincott-Raven, 1996: 1601
 2. Caplan LR: Caplan’s stroke, a clinical approach. Boston: Butterworth-
Heinemann, 2000: 17
 3. Hajjar KA, Esmon NL, Marcus AJ, Muller W: Vascular function in he-
mostasis. In: Beutler E, ed. Williams hematology. New York: McGraw-
Hill, 2001: 1451–70
 4. Chen ZM, Sandercock P, Pan HC et al: Indications for early aspirin use 
in acute ischemic stroke: A combined analysis of 40 000 randomized pa-
tients from the chinese acute stroke trial and the international stroke 
trial. On behalf of the CAST and IST collaborative groups. Stroke, 2000; 
31: 1240–49
 5. Moncada S, Vane JR: Arachidonic acid metabolites and the interac-
tions between platelets and blood-vessel walls. N Engl J Med, 1979; 300: 
1142–47
 6. Needleman P, Turk J, Jakschik BA et al: Arachidonic acid metabolism. 
Annu Rev Biochem, 1986; 55: 69–102
 7. Nelson DR, Kamataki T, Waxman DJ et al: The P450 superfamily: up-
date on new sequences, gene mapping, accession numbers, early trivial 
names of enzymes, and nomenclature. DNA Cell Biol, 1993; 12: 1–51
 8. Mestel F, Oetliker O, Beck E et al: Severe bleeding associated with de-
fective thromboxane synthetase. Lancet, 1980; 1: 157
 9. Tazawa R, Green ED, Ohashi K et al: Characterization of the complete 
genomic structure of human thromboxane synthase gene and function-
al analysis of its promoter. Arch Biochem Biophys 1996; 334: 349–56
 10. Wang LH, Tazawa R, Lang AQ, Wu KK: Alternate splicing of human 
thromboxane synthase mRNA. Arch Biochem Biophys, 1994; 315: 
273–78
 11. Chevalier D, Lo-Guidice JM, Sergent E et al: Identifi cation of genetic 
variants in the human thromboxane synthase gene (CYP5A1). Mutat 
Res, 2001; 432: 61–67
 12. Wang LH, Matijevic-Aleksic N, Hsu PY et al: Identifi cation of throm-
boxane A2 synthase active site residues by molecular modeling-guided 
site-directed mutagenesis. J Biol Chem, 1996; 271: 19970–75
 13. Bartsch H, Nair U, Risch A et al: Genetic polymorphism of CYP genes, 
alone or in combination, as a risk modifi er of tobacco-related cancers. 
Cancer Epidemiol Biomarkers Prev, 2000; 9: 3–28
 14. Adams HP Jr, Bendixen BH, Kappelle LJ et al: Classifi cation of subtype 
of acute ischemic stroke. Defi nitions for use in a multicenter clinical 
trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke, 
1993; 24: 35–41
 15.  De Backer G, Ambrosioni E, Borch-Johnsen K et al: European 
guidelines on cardiovascular disease prevention in clinical practice. Third 
Joint Task Force of European and other Societies on Cardiovascular Disease 
Prevention in Clinical Practice (constituted by representatives of eight 
societies and by invited experts). Atherosclerosis, 2004; 173: 381–91
 16. Dialyna IA, Miyakis S, Georgatou N, Spandidos DA: Genetic polymor-
phisms of CYP1A1, GSTM1 and GSTT1 genes and lung cancer risk. 
Oncol Rep, 2003; 10: 1829–35
 17. Fanning GC, Bunce M, Black CM, Welsh KI: Polymerase chain reaction 
haplotyping using 3’ mismatches in the forward and reverse primers: 
application to the biallelic polymorphisms of tumor necrosis factor and 
lymphotoxin alpha. Tissue Antigens, 1997; 50: 23–31
 18. Marez D, Legrand M, Sabbagh N et al: Polymorphism of the cyto-
chrome P450 CYP2D6 gene in a European population: characteriza-
tion of 48 mutations and 53 alleles, their frequencies and evolution. 
Pharmacogenetics, 1997; 7: 193–202
 19. Tanaka E: Update: genetic polymorphism of drug metabolizing enzymes 
in humans. J Clin Pharm Ther, 1999; 24: 323–29
 20. Davis SM, Donnan GA: Why lacunar syndromes are different and im-
portant. Stroke, 2004; 35: 1780–81
 21. Xia Z, Shen RF, Baek SJ, Tai HH: Expression of two different forms of 
cDNA for thromboxane synthase in insect cells and site-directed mutagen-
esis of a critical cysteine residue. Biochem J, 1993; 295 (Pt 2): 457–61
Med Sci Monit, 2009; 15(1): BR30-35 Kimouli M et al – Thromboxane synthase gene polymorhisms in stroke
BR35
BR
